Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198250 · ClinicalTrials.gov registry record · Phase 2
Venlafaxine for Hot Flashes After Breast Cancer
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00198250 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 75 participants.
The verdict
NCT00198250, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate Venlafaxine as a treatment option for hot flashes in breast cancer survivors. The goals of this study are to assess the effectiveness and toxicity of venlafaxine hydrochloride and identify the psychological, behavioral, and physical outcomes associated with relief of hot flashes in women following treatment for breast cancer.
Interventions
- DRUG venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2000-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198250
The ClinicalTrials.gov registry entry for NCT00198250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which venlafaxine is the first listed.
NCT00198250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198250 about?
NCT00198250 is a clinical study titled "Venlafaxine for Hot Flashes After Breast Cancer". The purpose of this study is to evaluate Venlafaxine as a treatment option for hot flashes in breast cancer survivors. The goals of this study are to assess the effectiveness and toxicity of venlafaxine hydrochloride and identify the psychological, behavioral, and physical outcomes associated with r...
What is the current status of trial NCT00198250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2000-05. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00198250?
The interventions under investigation include: venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00198250?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.